bismuth has been researched along with s 1743 in 47 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (6.38) | 29.6817 |
2010's | 23 (48.94) | 24.3611 |
2020's | 21 (44.68) | 2.80 |
Authors | Studies |
---|---|
Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
Aiello, F; Brandimarte, G; Elisei, W; Giorgetti, GM; Modeo, ME; Tursi, A | 1 |
Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
Hwang, JH; Hwang, TJ; Jeong, SH; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Park, YS; Song, IS | 1 |
Başer, O; Emer, O; Kadayifci, A; Kantarcioğlu, M; Kılcıler, G; Ozcan, A; Polat, Z; Uygun, A | 1 |
Algaba, A; Angueira, T; Barrio, J; Bermejo, F; Castro-Fernández, M; Del Castillo, F; Domínguez, JL; Federico, A; Fernández-Salazar, L; Gisbert, JP; Gómez, B; Gómez, J; Gravina, AG; Herranz, M; Lucendo, AJ; Marín, AC; Martorano, M; McNicholl, AG; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Pabón, M; Romano, M; Solís-Muñoz, P; Velayos, B | 1 |
Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L | 1 |
Graham, DY; Lu, H | 1 |
Gisbert, JP; Molina-Infante, J; Romano, M | 1 |
Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X | 1 |
Ding, Y; Fu, W; Song, Z; Suo, B; Tian, X; Wang, L; Xue, Y; Zhou, L | 1 |
Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH | 1 |
Alvaro, D; Bellesia, A; Brambilla, G; Bresci, G; D'Angelo, A; De Francesco, V; Di Ciaula, A; Eramo, A; Londoni, C; Manta, R; Portincasa, P; Ridola, L; Sacco, R; Scaccianoce, G; Tanzilli, A; Vassallo, R; Zullo, A | 1 |
Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A | 1 |
Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH | 1 |
De Francesco, V; Vaira, D; Zullo, A | 1 |
Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L | 1 |
Bair, MJ; Chang, CY; Chen, CC; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; Fang, YJ; Hsu, WF; Hu, WH; Kuo, CC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Twu, G; Wu, MS; Yang, TH; Yu, JJ | 1 |
Gan, HY; Huang, YM; Peng, TL; Su, KH; Yang, RJ; Yao, LY; Zhao, LL | 1 |
Kim, JM; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Soo In, C | 1 |
Chen, Y; Li, J; Liu, L; Lu, B; Wang, J | 1 |
Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
Graham, DY; Ji, Y; Liang, X; Long, X; Lu, H; Luo, L; Yu, L | 1 |
Fu, W; Song, Z; Zhou, L | 1 |
Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J | 1 |
Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
Chen, Y; Ke, H; Li, J; Liu, L; Lu, B; Wang, J; Wang, Z; Yang, C | 1 |
Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X | 1 |
Chen, H; Huang, K; Jin, D; Kong, S; Ye, F; Zhang, G | 1 |
Chen, CC; Chiang, TH; Graham, DY; Lee, YC; Liou, JM; Shun, CT; Tseng, PH; Wu, MS | 1 |
Alaa Eddin, K; Alassi, MW; Alhalabi, M; Cheha, K | 1 |
Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY | 1 |
An, P; Chen, ZF; Ding, XW; Guan, JL; He, Q; Hu, YL; Li, PY; Long, H; Luo, HS; Wu, SS; Xiong, JG; Zhou, L | 1 |
Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R | 1 |
Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK | 1 |
Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X | 1 |
Li, CL; Lu, HP; Ren, XL; Song, ZQ; Suo, BJ; Tian, XL; Yao, XY; Zhang, H; Zhang, YX; Zhou, LY | 1 |
He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL | 1 |
Du, Q; Han, Y; Li, Y; Lou, G; Lu, L; Wang, Y; Yan, H; Ye, J | 1 |
Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC | 1 |
Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L | 1 |
Chen, ZY; Han, JL; Han, XY; Huang, XX; Lan, C; Li, PY; Li, YQ; Liu, DN; Mo, CY; Pan, J; Tan, Y; Tang, J; Wang, QY; Wu, DH; Yang, WZ | 1 |
Chen, J; Ding, Z; Guo, Y; Han, Y; Huang, Y; Liang, X; Lu, H; Wang, J; Xu, P | 1 |
Czerniak, R; Gu, L; Hu, C; Men, R; Miao, J; Tang, J; Wang, W; Wang, Y; Yang, L; Yoshida, N | 1 |
38 trial(s) available for bismuth and s 1743
Article | Year |
---|---|
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 2007 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tetracycline; Time Factors; Treatment Outcome | 2010 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline; Young Adult | 2012 |
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Urea | 2015 |
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2015 |
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2017 |
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Medication Adherence; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Failure; Urea | 2017 |
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors | 2017 |
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2018 |
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2018 |
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2019 |
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome | 2019 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2020 |
The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Endoscopy; Esomeprazole; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Transmission; Organometallic Compounds; Proton Pump Inhibitors; Salts | 2021 |
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Syria; Tinidazole; Treatment Outcome; Young Adult | 2021 |
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome | 2021 |
Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2022 |
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2022 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2023 |
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Potassium Citrate; Tetracycline | 2023 |
Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2023 |
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Topics: Adult; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2023 |
9 other study(ies) available for bismuth and s 1743
Article | Year |
---|---|
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors | 2015 |
Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance--authors' reply.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Esomeprazole; Female; Humans; Levofloxacin; Male; Proton Pump Inhibitors | 2015 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Tablets; Tetracycline; Time Factors; Treatment Failure | 2017 |
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies | 2017 |
Is Double-Dose Esomeprazole With Bismuth Really Safe?
Topics: Bismuth; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors | 2017 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Risk Factors; Tetracycline; Treatment Failure | 2019 |
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; China; Drug Hypersensitivity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Penicillins; Prospective Studies; Treatment Outcome | 2019 |
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report.
Topics: Anti-Bacterial Agents; Bismuth; DNA, Bacterial; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Middle Aged; Penicillins; Recurrence; Retreatment; Treatment Outcome | 2021 |